newsfilter
← Latest News
GlobeNewswire·

IGM Biosciences Announces Third Quarter 2023 Financial Results

– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc.